76
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD

, , , , , , & show all
Pages 13-25 | Published online: 19 Dec 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Kirill Zhudenkov, Robert Palmér, Alexandra Jauhiainen, Gabriel Helmlinger, Oleg Stepanov, Kirill Peskov, Ulf G Eriksson & Ulrika Wählby Hamrén. (2021) Longitudinal FEV1 and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 101-111.
Read now
Dhuha Al-Sajee, Xuanzhi Yin & Gail M. Gauvreau. (2019) An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma. Expert Opinion on Pharmacotherapy 20:5, pages 609-620.
Read now
Donald P Tashkin & Charlie Strange. (2018) Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 2587-2601.
Read now
Peter M. A. Calverley, Helgo Magnussen, Marc Miravitlles & Jadwiga A. Wedzicha. (2017) Triple Therapy in COPD: What We Know and What We Don't. COPD: Journal of Chronic Obstructive Pulmonary Disease 14:6, pages 648-662.
Read now

Articles from other publishers (2)

Pinar Yildiz, Mesut Bayraktaroglu, Didem Gorgun & Kivanc Yuksel. (2019) Bronchodilator Efficacy of a Single-Dose 12/400-µg Formoterol/Budesonide Combination as a Dry Powder for Inhalation Delivered by Discair® in Adult Patients with Moderate-to-Severe Stable COPD: Open-Label, Single-Arm, Phase IV Trial. Clinical Drug Investigation 39:10, pages 991-1001.
Crossref
Mohamed Bayoumi-Ali, Richard John Sweeney, Luqman Hussain Wali, Doaa Farag & Favas Thaivalappil. 2018. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions 217 227 .